SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
GRTX

Galera Therapeutics, Inc. (OTC:GRTX)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$17.15+$1.53 (+9.80%)
 
Market cap
$17.8M
Insider Score
Health Score
Analyst consensus
Listed since
Nov 7, 2019
Market Cap$17.84M+328.8%
Revenue (ttm)$0
Net Income$149.03M+1021.8%
EPS$303.74+616.9%
Shares Out1.04M
PE Ratio0.06
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume420
Open$16.00
Previous Close$15.62
Day's Range$16.00 - $17.15
52-Week Range$0.09 - $30.00
Beta2.60
AnalystsBuy
Price Targetn/a
Earnings Daten/a
No price history available.

About GRTX

Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.

Address
101 Lindenwood Drive, Malvern, PA, 19355, US
Market Cap
18 million
Employees
3
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$1.40K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Fair
From GRTX’s reported statements · Q1 2026 (trailing 12 months) · 4 of 5 pillars
1 Day
+0.00%
5 Days
+0.00%
1 Month
-9.69%
6 Months
+90.56%
1 Year
+328.75%

$GRTX stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in GRTX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by GRTX's directors and management

Net Shares Purchased by Insiders−70k−35k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

GRTX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New GRTX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to GRTX from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from GRTX’s recent data — informational, not investment advice

Generating analysis…

Recent Insider Activity

Buys
0
Sells
1
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.